advanced breast cancer (metastatic) | versus single-agent chemotherapy No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| T1 vs T0 | | | | | T1 vs T0 | | | |
Trial | Treatments | Patients | Method |
---|
Gradishar, 2009 | weekly and every 3 week (q3w) nab-paclitaxel (n=302) vs. docetaxel (n=0) | first-line treatment in patients with MBC | Sample size: 302/0 Primary endpoint: FU duration: | Roy, 2008 | weekly nab (nanoparticle albumin-bound)-paclitaxel in combination with gemcitabine (n=50) vs. (n=0) | patients with previously untreated metastatic breast cancer | Sample size: 50/0 Primary endpoint: FU duration: |
|